Related Experiment Video

Updated: May 5, 2026

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.4K

Microbiome- metabolome signatures and Behavioral alterations in a progressive MPTP-induced mouse model of Parkinson's

Ankita Das1, Rabmit Das1, Arjoyeeta Das1

  • 1School of Biological Sciences, National Institute of Science Education and Research (NISER), PO: Jatni, Dist: Khurda, Odisha 752050, India; Center for Interdisciplinary Sciences (CIS), National Institute of Science Education and Research (NISER), PO: Jatni, Dist: Khurda, Odisha 752050, India; Homi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai, Maharashtra 400094, India.

Experimental Neurology
|February 22, 2026
PubMed

Insights

Parkinson's disease involves gut-brain axis dysfunction. Metabolite and microbiome changes in the gut correlate with brain pathology, offering potential early biomarkers and therapeutic targets for Parkinson's disease.

Area of Science:

  • Neuroscience
  • Microbiology
  • Metabolomics

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder with motor and metabolic symptoms.
  • Dopaminergic neuronal loss and inflammation characterize PD pathology in the brain.

Purpose of the Study:

  • Investigate gut-metabolite-brain interactions in Parkinson's disease.
  • Identify potential biomarkers and therapeutic targets within the gut microbiome and metabolome.

Main Methods:

  • Utilized a chronic MPTP-induced mouse model of Parkinson's disease.
  • Integrated behavioral, transcriptional, metabolomic (LC-MS), and microbiome (16S rRNA) analyses.
  • Performed correlation network analysis to link microbial taxa and metabolites.

Main Results:

  • MPTP-treated mice showed motor/non-motor deficits, increased alpha-synuclein, and midbrain inflammation.
  • Identified altered host and microbial metabolites (arginine/proline, sphingolipid, tryptophan, riboflavin metabolism).
  • Observed decreased Firmicutes/Bacteroidetes ratio and enrichment of lipopolysaccharide-producing bacteria linked to amino acid metabolism.

Conclusions:

  • Established a coordinated gut-metabolite-brain axis in Parkinson's disease.
  • Microbiome-derived metabolites are potential early biomarkers and therapeutic targets for PD.
  • Findings provide a framework for future validation in diverse PD models and cohorts.
Keywords:
Gut–brain AxisMPTPMetabolomicsMicrobiomeNeuroinflammationParkinson's disease

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

8.0K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.0K

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28